Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti Meaningfully Reduces Utilization of Healthcare Resources - Seite 2

• Cohorts were selected from patients prescribed NMCP and from within a national database of 100 million patients of those receiving OMCP; these groups were statistically matched using a propensity score with 257 subjects in each category for a total of 514 patients.
• 77% of patients were female.
• 31.1% of subjects in both groups experienced an ED visit or inpatient hospitalization during the 6-months prior to index.
• Patients treated with NCMP had 99 fewer physician office visits, 1 additional outpatient visit, 34 fewer inpatient hospitalizations and 84 fewer ED visits for DGP-related causes in the 6 month follow up period (image 1).
• Patients treated with NMCP had 124 fewer physician office visits, 55 fewer outpatient facility visits, 37 fewer inpatient hospitalizations, and 167 fewer ED visits for any cause in the 6-month follow-up period (image 2).
• Statistically, the likelihood of a patient treated having a DGP related physician office visit was 36% lower in the NMCP cohort (image 3). Similarly, for inpatient hospitalizations and emergency department visits the likelihood was 68% and 60% lower, respectively, for NMCP-treated patients versus OMCP.

Image 1:

Image 2:

Image 3:

Conclusions:

• In a matched comparison, NMCP-treated patients had significantly fewer nausea and vomiting or DGP-related office visits, ED visits, and inpatient hospitalizations in the 6 months following start of therapy.
• The reduction in DGP-related HCRU equated to an avoidance of 99 physician office visits, 84 fewer ED visits, and 34 fewer inpatient hospitalizations for NMCP patients versus OMCP patients in a 6-month period.
• Overall, the likelihood of a DGP patient treated with NMCP visiting the ED or being admitted to the hospital was less than half that of patients treated with OMCP during the same period.
  

Full data presentation at DDW 2023 available on Evoke Pharma website: https://investor.evokepharma.com/static-files/d45f574f-699a-48bd-86f1- ...

Lead author Dr. David C. Kunkel, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health commented, “This unique data set asserts that the route of metoclopramide administration is imperative for successful DGP treatment. The positive effects of nasal metoclopramide versus oral metoclopramide on patients and healthcare resources is worth noting and encouraging for the GI motility community. Considering the need for a more effective DGP therapy, it is important to utilize a treatment that can be absorbed by the patient, so it can work, such as GIMOTI.”